These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
556 related items for PubMed ID: 18666036
1. Daptomycin, a lipopeptide antibiotic in clinical practice. Weis F, Beiras-Fernandez A, Schelling G. Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036 [Abstract] [Full Text] [Related]
2. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. Steenbergen JN, Alder J, Thorne GM, Tally FP. J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644 [Abstract] [Full Text] [Related]
3. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ. Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [Abstract] [Full Text] [Related]
4. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Carpenter CF, Chambers HF. Clin Infect Dis; 2004 Apr 01; 38(7):994-1000. PubMed ID: 15034832 [Abstract] [Full Text] [Related]
5. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Kanafani ZA, Corey GR. Expert Rev Anti Infect Ther; 2007 Apr 01; 5(2):177-84. PubMed ID: 17402833 [Abstract] [Full Text] [Related]
6. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Ardura MI, Mejías A, Katz KS, Revell P, McCracken GH, Sánchez PJ. Pediatr Infect Dis J; 2007 Dec 01; 26(12):1128-32. PubMed ID: 18043450 [Abstract] [Full Text] [Related]
7. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. Cervera C, Castañeda X, Pericas JM, Del Río A, de la Maria CG, Mestres C, Falces C, Marco F, Moreno A, Miró JM. Int J Antimicrob Agents; 2011 Nov 01; 38(5):365-70. PubMed ID: 21420835 [Abstract] [Full Text] [Related]
8. The use of daptomycin for Staphylococcus aureus infections in critical care medicine. Alder J. Crit Care Clin; 2008 Apr 01; 24(2):349-63, ix-x. PubMed ID: 18361950 [Abstract] [Full Text] [Related]
9. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias]. Hernández Martí V, Romá Sánchez E, Salavert Lletí M, Bosó Ribelles V, Poveda Andrés JL. Rev Esp Quimioter; 2007 Sep 01; 20(3):261-76. PubMed ID: 18080024 [Abstract] [Full Text] [Related]
10. [The second life of daptomycin: analysis of a successful come-back]. Decousser JW, Doucet Populaire F. Med Mal Infect; 2008 Dec 01; 38 Spec No 2():1-3. PubMed ID: 19185200 [No Abstract] [Full Text] [Related]
11. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections]. Mathiesen L, Midtvedt T, Solberg CO. Tidsskr Nor Laegeforen; 2006 Sep 21; 126(18):2383-4. PubMed ID: 16998552 [Abstract] [Full Text] [Related]
12. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. French GL. J Antimicrob Chemother; 2006 Dec 21; 58(6):1107-17. PubMed ID: 17040922 [Abstract] [Full Text] [Related]
13. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. Skiest DJ. J Clin Microbiol; 2006 Feb 21; 44(2):655-6. PubMed ID: 16455939 [Abstract] [Full Text] [Related]
14. Daptomycin: a review 4 years after first approval. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Pharmacology; 2008 Feb 21; 81(2):79-91. PubMed ID: 17940348 [Abstract] [Full Text] [Related]